Condition: Intrahepatic Cholangiocarcinoma · Sponsor: Anhui Provincial Hospital
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery
This description comes directly from the study's public registry record.
Ji-Zhou Wang · +86 13836135864 · wangjoe@ustc.edu.cn
Always discuss trial participation with your own doctor first.
| No.2 People's Hospital of Fuyang city | Fuyang, Anhui, China | Recruiting |
| Anhui province hospital | Hefei, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06664021